GlassScriptPhysician profile
Jeffrey Harris
NPI 1023457991
$10,172.71
in general payments reported to CMS, 2019-2025
40 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,467 · 2020: $1,027 · 2021: $1,472 · 2022: $1,516 · 2023: $1,934 · 2024: $1,627 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,674 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,673.95 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,835.64 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $1,312.40 | 2019-2025 | |
| Amgen INC. | $1,001.45 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $879.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $721.88 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $660.63 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $559.79 | 2019-2024 | Xarelto |
| Pfizer INC. | $471.29 | 2019-2025 | |
| Lilly USA, LLC | $337.39 | 2019-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $320.04 | 2019-2024 | Trintellix |
| Astellas Pharma US INC | $285.47 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $248.95 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Shield Therapeutics INC | $164.33 | 2023-2024 | Accrufer |
| Novartis Pharmaceuticals Corporation | $147.42 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $132.25 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.